Reuters logo
BRIEF-Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102
March 23, 2017 / 12:19 PM / 6 months ago

BRIEF-Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102

March 23 (Reuters) - Aeglea Bio Therapeutics Inc

* Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102 for treatment of Arginase I deficiency at 2017 ACMG annual clinical genetics meeting

* Treatment with AEB1102 well tolerated, no related adverse events or clinically significant abnormal laboratory results reported

* Study showed that single, intermittent doses of AEB1102 resulted in reduction of arginine in blood to normal levels Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below